→ Since the bipartisan bill compelling pharmaceutical companies to display drug prices as part of their television advertisements was torpedoed in September, the biopharma drug pricing controversy has only intensified. Eli Lilly $LLY, which announced an $8 billion bet on Loxo Oncology $LLY on Monday, has set up a page (https://www.lillypricinginfo.com/) on its website so patients can look up the prices carried by its drugs. According to Bloomberg, which first reported the news, Lilly will air television ads brandishing the page in tandem with a toll-free helpline.
This is part of a voluntary PhRMA initiative. Other drug companies that have committed to participating will have to start doing this by April 15 at the latest (but the companies police themselves so not clear what would happen if they missed this deadline) https://t.co/hDRkXkKsJn
— Jacquie Lee (@_jacquie_lee) January 8, 2019
→ Biopharma contract drug developer and manufacturer Catalent $CTLT, which bought out Juniper Pharmaceuticals last year to beef up its early drug development offerings in the UK, is planning to invest $200 million in its biologics business over three years at its manufacturing sites in Madison, Wisconsin and Bloomington, Indiana, it said on Monday.
→ Weeks after initiating a Phase III study for experimental bladder cancer therapy, Israel-based Anchiano Therapeutics — formerly known as BioCanCell — has filed for an IPO worth up to $35 million. No pricing terms were disclosed.
→ Gene therapy developer Apic Bio, which was spun out of the University of Massachusetts Medical School, scored $40 million in a Series A round led by Morningside Venture Investments. The company has also hired Scott Loiler, who formerly worked with Nationwide Children’s Hospital, as CTO.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 45,100+ biopharma pros who read Endpoints News by email every day.Free Subscription